Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease

BACKGROUND: Infliximab original has changed the natural history of inflammatory bowel diseases (IBD) over the past two decades. However, the recent expiration of its patent has allowed the entry of the first Infliximab biosimilar into the European and Spanish markets. Currently switching drugs data i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:World J Gastroenterol
Main Authors: Guerra Veloz, María Fernanda, Argüelles-Arias, Federico, Castro Laria, Luisa, Maldonado Pérez, Belén, Benítez Roldan, Antonio, Perea Amarillo, Raúl, Merino Bohórquez, Vicente, Calleja, Miguel Angel, Caunedo Álvarez, Ángel, Vilches Arenas, Ángel
Formato: Artigo
Idioma:Inglês
Publicado: Baishideng Publishing Group Inc 2018
Assuntos:
Observational Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6295832/
https://ncbi.nlm.nih.gov/pubmed/30581277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v24.i46.5288
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares